742-20-1 Usage
Description
Cyclopenthiazide is a thiazide diuretic, a medication that promotes the excretion of water and electrolytes, particularly sodium and chloride, by inhibiting the sodium chloride symporter in the kidneys.
Used in Pharmaceutical Industry:
Cyclopenthiazide is used as an antihypertensive agent for the treatment of hypertension, helping to lower blood pressure and reduce the risk of cardiovascular complications.
Used in Nephrology:
Cyclopenthiazide is used as a diuretic for the treatment of edema caused by kidney disease, aiding in the management of fluid retention and alleviating symptoms associated with kidney dysfunction.
Used in Hepatology:
Cyclopenthiazide is used as a diuretic for the treatment of edema caused by liver cirrhosis, helping to reduce fluid accumulation and improve the overall condition of patients with liver-related issues.
Used in Gynecology:
Cyclopenthiazide is used as a diuretic for the treatment of pre-menstrual syndrome-related edema, providing relief from fluid retention and associated discomfort during the menstrual cycle.
World Health Organization (WHO)
Cyclopenthiazide, a thiazide diuretic, was introduced in 1968. It
continues to be used mainly in combination drugs.
Clinical Use
Thiazide diuretic:
Hypertension
Heart failure
Oedema
Drug interactions
Potentially hazardous interactions with other drugs
Analgesics: increased risk of nephrotoxicity with
NSAIDs; antagonism of diuretic effect. Anti-arrhythmics: hypokalaemia leads to increased
cardiac toxicity; effects of lidocaine and mexiletine
antagonised.
Antibacterials: avoid administration with
lymecycline.
Antidepressants: increased risk of hypokalaemia
with reboxetine; enhanced hypotensive effect with
MAOIs; increased risk of postural hypotension with
tricyclics.
Antiepileptics: increased risk of hyponatraemia with
carbamazepine.
Antifungals: increased risk of hypokalaemia with
amphotericin.
Antihypertensives: enhanced hypotensive effect;
increased risk of first dose hypotension with postsynaptic alpha-blockers like prazosin; hypokalaemia
increases risk of ventricular arrhythmias with sotalol.
Antipsychotics: hypokalaemia increases risk
of ventricular arrhythmias with amisulpride;
enhanced hypotensive effect with phenothiazines;
hypokalaemia increases risk of ventricular
arrhythmias with pimozide - avoid.
Atomoxetine: hypokalaemia increases risk of
ventricular arrhythmias.
Cardiac glycosides: increased toxicity if hypokalaemia
occurs.
Ciclosporin: increased risk of nephrotoxicity and
possibly hypomagnesaemia.
Cytotoxics: increased risk of ventricular arrhythmias
due to hypokalaemia with arsenic trioxide; increased
risk of nephrotoxicity and ototoxicity with platinum
compounds.
Lithium: excretion reduced, increased toxicity
Metabolism
Cyclopenthiazide appears to be entirely excreted
unchanged in the urine.
Check Digit Verification of cas no
The CAS Registry Mumber 742-20-1 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 7,4 and 2 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 742-20:
(5*7)+(4*4)+(3*2)+(2*2)+(1*0)=61
61 % 10 = 1
So 742-20-1 is a valid CAS Registry Number.
InChI:InChI=1/C13H18ClN3O4S2/c14-9-6-10-12(7-11(9)22(15,18)19)23(20,21)17-13(16-10)5-8-3-1-2-4-8/h6-8,13,16-17H,1-5H2,(H2,15,18,19)
